
    
      This is a 2 part, Phase 2/3 multi-center, double blinded, placebo-controlled study to assess
      the safety, tolerability, and efficacy of oral niclosamide (ANA001) in moderate and severe
      hospitalized COVID-19 patients compared to placebo.
    
  